Review: Beyond the NLRP3 inflammasome: Autoinflammatory diseases reach adolescence

Arthritis and Rheumatism

Volumn 65, Issue 5, 2013, Pages 1137-1147

  Gattorno, Marco ^a   Martini, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ADOLESCENCE; AUTOINFLAMMATORY DISEASE; CASPASE RECRUITMENT DOMAIN 14 MEDIATED PUSTULAR PSORIASIS; CELL STRESS; CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WIT LIPODYSTROPHY AND ELEVATED TEMPERATURE; CINCA SYNDROME; DEFICIENCY OF THE INTEREUKIN 1 RECEPTOR ANTAGONIST; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME TYPE 2; FAMILIAL MEDITERRANEAN FEVER; HUMAN; MEVALONATE KINASE DEFICIENCY; NONHUMAN; OXIDATIVE STRESS; PAPA SYNDROME; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MULTIFACTORIAL INHERITANCE; MUTATION;

CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FAMILIAL MEDITERRANEAN FEVER; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; MULTIFACTORIAL INHERITANCE; MUTATION;

MLCS; MLOWN;

EID: 84876548007     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37882     Document Type: Review

References (87)

1. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25-31.
2. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90: 797-807.
3. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
4. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD,. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5.
5. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 1984; 81: 7907-11.
6. Ferrari D, Chiozzi P, Falzoni S, Dal SM, Melchiorri L, Baricordi OR, et al. Extracellular ATP triggers IL-1β release by activating the purinergic P2Z receptor of human macrophages. J Immunol 1997; 159: 1451-8.
7. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A,. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 1999; 10: 1463-75.
8. Shaw PJ, Lamkanfi M, Kanneganti TD,. NOD-like receptor (NLR) signaling beyond the inflammasome. Eur J Immunol 2010; 40: 624-7.
9. Martinon F, Burns K, Tschopp J,. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Mol Cell 2002; 10: 417-26.
10. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J,. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-25.
11. Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, Pelagatti MA, et al. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56: 3138-48.
12. Hawkins PN, Lachmann HJ, McDermott MF,. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348: 2583-4.
13. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-85.
14. Lovell DJ, Bowyer SL, Solinger AM,. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005; 52: 1283-6.
15. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581-92.
16. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52.
17. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (Interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58: 2432-42.
18. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
19. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70: 2095-102.
20. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J,. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
21. Masters SL, Simon A, Aksentijevich I, Kastner DL,. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009; 27: 621-68.
22. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008; 105: 9035-40.
23. Masters SL, O'Neill LA,. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol Med 2011; 17: 276-82.
24. So A, De Smedt T, Revaz S, Tschopp J,. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
25. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 6810: 1613-7.
26. Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, et al. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One 2011; 6: e27923.
27. Dinarello CA, Donath MY, Mandrup-Poulsen T,. Role of IL-1β in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 314-21.
28. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [published erratum appears in Nature 2010;466:652]. Nature 2010; 464: 1357-61.
29. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
30. Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA,. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52: 1794-803.
31. Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A,. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60: 264-8.
32. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A,. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008; 121: 260-2.
33. McGonagle D, McDermott MF,. A proposed classification of the immunological diseases. PLoS Med 2006; 3: e297.
34. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I,. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011; 41: 265-71.
35. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P,. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-201.
36. Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2012. E-pub ahead of print.
37. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci U S A 2006; 103: 9982-7.
38. Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 2008; 112: 1794-803.
39. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death Differ 2007; 14: 1457-66.
40. Yu JW, Fernandes-Alnemri T, Datta P, Wu J, Juliana C, Solorzano L, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007; 28: 214-27.
41. Gavrilin MA, Abdelaziz DH, Mostafa M, Abdulrahman BA, Grandhi J, Akhter A, et al. Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol 2012; 188: 3469-77.
42. Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011; 34: 755-68.
43. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003; 100: 13501-6.
44. Jacobs JC, Goetzl EJ,. "Streaking leukocyte factor," arthritis, and pyoderma gangrenosum. Pediatrics 1975; 56: 570-8.
45. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-37.
46. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
47. Blau EB,. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985; 107: 689-93.
48. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20.
49. Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F,. NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin Immunol 2010; 134: 251-61.
50. Martin TM, Zhang Z, Kurz P, Rose CD, Chen H, Lu H, et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009; 60: 611-8.
51. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012; 90: 784-95.
52. Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 2008; 105: 1614-9.
53. Williams KL, Lich JD, Duncan JA, Reed W, Rallabhandi P, Moore C, et al. The CATERPILLER protein Monarch-1 is an antagonist of Toll-like receptor-, tumor necrosis factor α-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem 2005; 280: 39914-24.
54. Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R, et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of a NLRP12 mutation. Arthritis Rheum 2011; 63: 830-9.
55. Tschopp J, Schroder K,. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10: 210-5.
56. Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A,. DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol 2009; 86: 549-55.
57. Tassi S, Carta S, Vene R, Delfino L, Ciriolo MR, Rubartelli A,. Pathogen-induced interleukin-1β processing and secretion is regulated by a biphasic redox response. J Immunol 2009; 183: 1456-62.
58. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V,. Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 2011; 187: 613-7.
59. Tassi S, Carta S, Delfino L, Caorsi R, Martini A, Gattorno M, et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion. Proc Natl Acad Sci U S A 2010; 107: 9789-94.
60. Rubartelli A, Gattorno M, Netea MG, Dinarello CA,. Interplay between redox status and inflammasome activation. Trends Immunol 2011; 32: 559-66.
61. Jeru I, Hentgen V, Normand S, Duquesnoy P, Cochet E, Delwail A, et al. Role of interleukin-1β in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. Arthritis Rheum 2011; 63: 2142-8.
62. D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54: 998-1008.
63. Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108: 1320-7.
64. Todd I, Radford PM, Daffa N, Bainbridge SE, Powell RJ, Tighe PJ,. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum 2007; 56: 2765-73.
65. Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 2010; 107: 9801-6.
66. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519-33.
67. Hasnain SZ, Lourie R, Das I, Chen AC, McGuckin MA,. The interplay between endoplasmic reticulum stress and inflammation. Immunol Cell Biol 2012; 90: 260-70.
68. Levine B, Mizushima N, Virgin HW,. Autophagy in immunity and inflammation. Nature 2011; 469: 323-35.
69. Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, Omenetti A, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 2012. E-pub ahead of print.
70. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222-30.
71. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
72. Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012; 64: 908-13.
73. Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J, et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2012; 71: 2035-43.
74. Van der Meer JW, Vossen JM, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984; 1: 1087-90.
75. Van der Burgh R, Ter Haar NM, Boes ML, Frenkel J,. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol 2012. E-pub ahead of print.
76. Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM, Wanders RJ, et al. Lack of isoprenoid products raises ex vivo interleukin-1β secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002; 46: 2794-803.
77. Pontillo A, Paoluzzi E, Crovella S,. The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 2010; 18: 844-7.
78. Wu YW, Oesterlin LK, Tan KT, Waldmann H, Alexandrov K, Goody RS,. Membrane targeting mechanism of Rab GTPases elucidated by semisynthetic protein probes. Nat Chem Biol 2010; 6: 534-40.
79. Kim I, Xu W, Reed JC,. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013-30.
80. Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010; 87: 866-72.
81. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, et al. Proteasome assembly defect due to a proteasome subunit β type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A 2011; 108: 14914-9.
82. Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012; 64: 895-907.
83. Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 2011; 121: 4150-60.
84. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012; 366: 330-8.
85. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36: 388-400.
86. Strowig T, Henao-Mejia J, Elinav E, Flavell R,. Inflammasomes in health and disease. Nature 2012; 481: 278-86.
87. Thurnher M, Nussbaumer O, Gruenbacher G,. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012; 18: 3524-31.